ABMed undergoes rigorous WHO evaluation
From July 6 to 9, 2026, the Agence Béninoise du Médicament et des autres produits de Santé (ABMed) underwent a comprehensive assessment by a panel of World Health Organization (WHO) experts. Over four intensive days, the delegation scrutinized the agency’s regulatory framework, operational procedures, and compliance mechanisms—from drug approval processes to post-market surveillance and clinical trials.
The audit, conducted in Cotonou, evaluated every facet of Benin’s pharmaceutical governance to ensure alignment with international standards. Preliminary findings, shared on July 9, highlighted significant progress, positioning the country on the brink of securing the WHO’s Maturity Level 3 certification—a milestone in public health security.
What does WHO’s Maturity Level 3 mean for Benin?
The prestigious Maturity Level 3 classification indicates a country’s regulatory system is stable, fully functional, and capable of exerting rigorous control over pharmaceutical products within its borders. For Benin, this would mean:
- A foolproof mechanism to combat counterfeit and substandard medicines
- Enhanced trust from global health partners and investors
- Stronger local pharmaceutical production and export potential
- Guaranteed access to safe, high-quality medications for citizens
Beyond its health implications, this certification would serve as a strategic asset, reinforcing Benin’s role as a regional leader in pharmaceutical governance.
Decade-long reforms reach a defining moment
During the evaluation’s closing ceremony, Health Minister Professor Benjamin Hounkpatin hailed the progress as a testament to Benin’s commitment to systemic reform. Since 2017, the government has overhauled the pharmaceutical sector by:
- Transforming the former pharmacy directorate into an autonomous agency (ABMed)
- Strengthening legal frameworks to tighten oversight
- Implementing robust monitoring and enforcement measures
The minister underscored the state’s unwavering support to ensure ABMed meets all remaining WHO requirements for full certification.
West Africa’s next pharmaceutical hub?
If Benin secures Maturity Level 3, it will join Senegal as the second Francophone nation in West Africa to achieve this recognition. This achievement would cement Benin’s reputation as a model of pharmaceutical excellence in the subregion, proving that with political will and technical precision, African nations can meet global benchmarks.
A new chapter for Benin’s public health
The 2026 WHO mission marks a watershed moment for Benin’s healthcare sector. While the preliminary results are promising, ABMed must now finalize outstanding recommendations to officially transition to Maturity Level 3. This certification would not only safeguard patient health but also symbolize Benin’s sovereignty in pharmaceutical production—a goal now within reach.
